Azole Resistance in Aspergillus Fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?

Overview

Journal Mycopathologia

Specialties Microbiology
Pharmacology

Date 2017 Jun 28

PMID 28653258

Citations 17

Authors

A Hamprecht

F Morio

O Bader

P Le Pape

J Steinmann

E Dannaoui

Affiliations

Soon will be listed here.

Abstract

Aspergillus fumigatus is the most frequent filamentous fungus isolated from respiratory specimens from patients with cystic fibrosis (CF). Triazoles are the most widely used antifungals in the treatment of allergic bronchopulmonary aspergillosis (ABPA) and invasive aspergillosis (IA) in CF patients. Treatment success could be severely compromised by the occurrence of azole-resistant A. fumigatus (ARAf), which is increasingly reported worldwide from both clinical samples and the environment. In previous studies, ARAf has been detected in up to 8% of CF patients. Isolates from CF patients requiring antifungal treatment should therefore be routinely subjected to antifungal susceptibility testing. The optimal treatment of ABPA or IA in CF patients with azole-resistant isolates has not been established; treatment options include liposomal amphotericin B i.v. and/or echinocandins i.v.

Citing Articles

Fungal Colonization of the Airways of Patients with Cystic Fibrosis: the Role of the Environmental Reservoirs.

Ravenel K, Guegan H, Gastebois A, Bouchara J, Gangneux J, Giraud S Mycopathologia. 2024; 189(2):19.

PMID: 38407729 DOI: 10.1007/s11046-023-00818-x.

The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Section from Three French Hospitals.

Djenontin E, Costa J, Mousavi B, Nguyen L, Guillot J, Delhaes L Microorganisms. 2023; 11(10).

PMID: 37894087 PMC: 10609271. DOI: 10.3390/microorganisms11102429.

Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis.

Tomomatsu K, Yasuba H, Ishiguro T, Imokawa S, Hara J, Soeda S Sci Rep. 2023; 13(1):5468.

PMID: 37015988 PMC: 10073186. DOI: 10.1038/s41598-023-32246-8.

Synergy Between Filtrates And Voriconazole Against Biofilm Is Less for Mucoid Isolates From Persons With Cystic Fibrosis.

Sass G, Marsh J, Shrestha P, Sabino R, Stevens D Front Cell Infect Microbiol. 2022; 12:817315.

PMID: 35493738 PMC: 9047052. DOI: 10.3389/fcimb.2022.817315.

Aspergillus fumigatus In-Host HOG Pathway Mutation for Cystic Fibrosis Lung Microenvironment Persistence.

Ross B, Lofgren L, Ashare A, Stajich J, Cramer R mBio. 2021; 12(4):e0215321.

PMID: 34465017 PMC: 8406193. DOI: 10.1128/mBio.02153-21.

References

Paul S, Diekema D, Moye-Rowley W . Contributions of Aspergillus fumigatus ATP-binding cassette transporter proteins to drug resistance and virulence. Eukaryot Cell. 2013; 12(12):1619-28. PMC: 3889576. DOI: 10.1128/EC.00171-13. View

Brown K, Rosenthal M, Bush A . Fatal invasive aspergillosis in an adolescent with cystic fibrosis. Pediatr Pulmonol. 1999; 27(2):130-3. DOI: 10.1002/(sici)1099-0496(199902)27:2<130::aid-ppul10>3.0.co;2-1. View

Spiess B, Seifarth W, Merker N, Howard S, Reinwald M, Dietz A . Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother. 2012; 56(7):3905-10. PMC: 3393401. DOI: 10.1128/AAC.05902-11. View

Steinmann J, Hamprecht A, Vehreschild M, Cornely O, Buchheidt D, Spiess B . Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany. J Antimicrob Chemother. 2015; 70(5):1522-6. DOI: 10.1093/jac/dku566. View

LiPuma J . The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010; 23(2):299-323. PMC: 2863368. DOI: 10.1128/CMR.00068-09. View

Fraczek M, Bromley M, Buied A, Moore C, Rajendran R, Rautemaa R . The cdr1B efflux transporter is associated with non-cyp51a-mediated itraconazole resistance in Aspergillus fumigatus. J Antimicrob Chemother. 2013; 68(7):1486-96. DOI: 10.1093/jac/dkt075. View

Chishimba L, Langridge P, Powell G, Niven R, Denning D . Efficacy and safety of nebulised amphotericin B (NAB) in severe asthma with fungal sensitisation (SAFS) and allergic bronchopulmonary aspergillosis (ABPA). J Asthma. 2014; 52(3):289-95. DOI: 10.3109/02770903.2014.958853. View

Chishimba L, Niven R, Cooley J, Denning D . Voriconazole and posaconazole improve asthma severity in allergic bronchopulmonary aspergillosis and severe asthma with fungal sensitization. J Asthma. 2012; 49(4):423-33. DOI: 10.3109/02770903.2012.662568. View

Balajee S, Houbraken J, Verweij P, Hong S, Yaghuchi T, Varga J . Aspergillus species identification in the clinical setting. Stud Mycol. 2008; 59:39-46. PMC: 2275201. DOI: 10.3114/sim.2007.59.05. View

10.

Amorim A, Guedes-Vaz L, Araujo R . Susceptibility to five antifungals of Aspergillus fumigatus strains isolated from chronically colonised cystic fibrosis patients receiving azole therapy. Int J Antimicrob Agents. 2010; 35(4):396-9. DOI: 10.1016/j.ijantimicag.2009.12.007. View

11.

Stevens D, Moss R, Hernandez C, Clemons K, Martinez M . Effect of Media Modified To Mimic Cystic Fibrosis Sputum on the Susceptibility of Aspergillus fumigatus, and the Frequency of Resistance at One Center. Antimicrob Agents Chemother. 2016; 60(4):2180-4. PMC: 4808157. DOI: 10.1128/AAC.02649-15. View

12.

Chryssanthou E . In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. acquired resistance to itraconazole. Scand J Infect Dis. 1997; 29(5):509-12. DOI: 10.3109/00365549709011864. View

13.

Moreira A, Silva D, Reis Ferreira A, Delgado L . Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis: a systematic review. Clin Exp Allergy. 2014; 44(10):1210-27. DOI: 10.1111/cea.12333. View

14.

van der Linden J, Camps S, Kampinga G, Arends J, Debets-Ossenkopp Y, Haas P . Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles. Clin Infect Dis. 2013; 57(4):513-20. DOI: 10.1093/cid/cit320. View

15.

Snelders E, Camps S, Karawajczyk A, Schaftenaar G, Kema G, van der Lee H . Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS One. 2012; 7(3):e31801. PMC: 3291550. DOI: 10.1371/journal.pone.0031801. View

16.

Mellado E, Garcia-Effron G, Alcazar-Fuoli L, Melchers W, Verweij P, Cuenca-Estrella M . A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother. 2007; 51(6):1897-904. PMC: 1891382. DOI: 10.1128/AAC.01092-06. View

17.

Aaron S, Vandemheen K, Freitag A, Pedder L, Cameron W, Lavoie A . Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One. 2012; 7(4):e36077. PMC: 3340414. DOI: 10.1371/journal.pone.0036077. View

18.

MAGUIRE C, Hayes J, Hayes M, Masterson J, Fitzgerald M . Three cases of pulmonary aspergilloma in adult patients with cystic fibrosis. Thorax. 1995; 50(7):805-6. PMC: 474659. DOI: 10.1136/thx.50.7.805. View

19.

Shoseyov D, Brownlee K, Conway S, Kerem E . Aspergillus bronchitis in cystic fibrosis. Chest. 2006; 130(1):222-6. DOI: 10.1378/chest.130.1.222. View

20.

Stevens D, Schwartz H, Lee J, Moskovitz B, Jerome D, Catanzaro A . A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med. 2000; 342(11):756-62. DOI: 10.1056/NEJM200003163421102. View